STAT Plus: New long-term data on @genentech’s groundbreaking drug for MS show it has continued to work — and that patients who started the drug earlier got the most benefit. https://buff.ly/2yvi0cN 

STAT Plus: New long-term data on @genentech’s groundbreaking drug for MS show it has continued to work — and that patients who started the drug earlier got the most benefit. https://buff.ly/2yvi0cN 

More From BioPortfolio on "STAT Plus: New long-term data on @genentech’s groundbreaking drug for MS show it has continued to work — and that patients who started the drug earlier got the most benefit. https://buff.ly/2yvi0cN "